Morgan Stanley Eq Rx, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$1.66 - $2.31 $4.31 Million - $6 Million	-2,596,956 Reduced 34.81%	4,863,294 $10.8 Million
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $1.17 Million - $1.42 Million	726,558 Added 10.79%	7,460,250 $13.9 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $227,917 - $358,337	126,621 Added 1.92%	6,733,692 $13.1 Million
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $13.1 Million - $35.2 Million	6,401,051 Added 3107.0%	6,607,071 $16.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.94 - $5.99 $84,224 - $536,709	-89,601 Reduced 30.31%	206,020 $1.02 Million
Q2 2022 Oct 27, 2022	BUY	$3.2 - $5.69 $834,595 - $1.48 Million	260,811 Added 749.24%	295,621 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.69 $834,595 - $1.48 Million	260,811 Added 749.24%	295,621 $1.39 Million
Q1 2022 Oct 27, 2022	SELL	$2.8 - $7.39 $730,270 - $1.93 Million	-260,811 Reduced 88.22%	34,810 $144,000
Q1 2022 May 13, 2022	BUY	$2.8 - $7.39 $91,868 - $242,465	32,810 Added 1640.5%	34,810 $144,000
Q4 2021 Feb 14, 2022	BUY	$5.92 - $9.98 $11,840 - $19,960	2,000 New	2,000 $14,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.